NKGen Biotech
CompanyUnited StatesFounded 2017
NKGen Biotech develops one asset, in phase 1 (SNK01 in moderate Alzheimer disease). Mostly cell therapy acting on inflammation; based in the United States, founded in 2017.
- 1
- Asset
- Furthest stage
- Phase 1
- 1
- Trial
- 0
- Signals
Pipeline
1Autologous natural killer (NK) cell therapy targeting neuroinflammation and abnormal protein aggregates.
Phase 1, Cell therapy, Inflammation, moderate Alzheimer disease
Full company profiles: pipeline, trials, funding and people.
In the full profile
- Evidence behind the mechanisms1
- Trials1
- Signals1
- Similar companies6